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Early pregnancy loss:  
Pretreat with mifepristone?
Yes. While medical management of early pregnancy loss 
with misoprostol frequently results in treatment failure, 
pretreating with mifepristone can increase efficacy. 
PRACTICE CHANGER
Pretreat patients with oral mifepristone prior 
to using vaginal misoprostol to increase the 
efficacy of medical management of early preg-
nancy loss over that with misoprostol alone.
STRENGTH OF RECOMMENDATION
B: Based on a single, well-executed, random-
ized controlled trial.1
Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone pretreatment 
for the medical management of early pregnancy loss.  N Engl J Med. 
2018;378:2161-2170.
ILLUSTRATIVE CASE
Jenny is a 29-year-old G2P1001 woman who 
presents to your clinic for a missed period. Her 
last menstrual period was about 10 weeks ago. 
She is found to have a positive pregnancy test 
in the office. On examination, her uterus is 
nontender and consistent in size with gestation 
of 7 weeks. She denies any bleeding or cramp-
ing. On ultrasound, you see a gestational sac 
measuring 28 mm and no embryo. You confirm 
early pregnancy loss. Jenny is sad about this 
diagnosis. She does not wish to proceed with 
expectant management and is hopeful to avoid 
a surgical procedure. How do you counsel her 
regarding medical management?
Early pregnancy loss or first trimester miscarriage is estimated to occur in about 1 million women in the United 
States annually and is the most common 
complication of early pregnancy.2,3 Early 
pregnancy loss is defined as a nonviable, in-
trauterine pregnancy with either an empty 
gestational sac or a gestational sac contain-
ing an embryo or fetus without fetal heart 
activity within the first 12 weeks 6 days of 
gestation.4 
Once early pregnancy loss is confirmed 
by ultrasound, expectant management with 
no intervention is an acceptable treatment 
option. Women generally prefer active man-
agement, either medically or with surgical 
evacuation.5,6 Misoprostol 800 mcg admin-
istered vaginally or orally has been the ac-
cepted medication regimen for medical 
management.5 However, failure rates with 
misoprostol have been reported to be as high 
as 40%, particularly among women with a 
closed cervical os, who then require repeat 
dosing of misoprostol or surgical evacuation.6 
STUDY SUMMARY
Mifepristone before misoprostol  
improves efficacy for early pregnancy loss
The PreFaiR (Comparative Effectiveness of 
Pregnancy Failure Management Regimens) 
study was a randomized trial that took place at 
3 US centers. The study was designed to assess 
the safety and efficacy of pretreatment with 
oral mifepristone prior to use of vaginal miso-
prostol for the medical management of early 
pregnancy loss.1 
Three hundred women, ≥ 18 years and 
undergoing medical management for early 
pregnancy loss, were randomized to receive 
misoprostol 800 mcg vaginally alone or mife-
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pristone 200 mg orally followed by misopros-
tol 800 mcg vaginally 24 hours later. 
❚ Inclusion and exclusion criteria. Wom-
en who showed a nonviable intrauterine preg-
nancy at 5 to 12 weeks’ gestation by ultrasound 
were eligible for the study. Exclusion criteria 
included incomplete or inevitable abortion, 
contraindications to either study drug, viable 
or ectopic pregnancy, hemoglobin < 9.5 g/dL, 
current use of anticoagulants or the presence 
of a clotting disorder, and pregnancy with an 
intrauterine device in place. 
❚ Outcomes. The primary outcome was 
gestational sac expulsion by the first follow-
up visit and no additional interventions with-
in 30 days of treatment. Secondary outcomes 
included acceptability of treatment, adverse 
events, and clinical characteristics associated 
with successful expulsion. 
❚ Demographics. The mean age of the 
study participants in both groups was ~30 
years, and there was a similar percentage of 
participants by self-reported race and ethnic-
ity in both groups (~44% black, ~35% white, 
and ~25% Hispanic). The majority of partici-
pants in both groups were at 6 to 8 weeks’ ges-
tation and had been pregnant at least 3 times. 
❚ Results. Researchers were able to evaluate 
297 women at the initial follow-up. Of the wom-
en who received mifepristone and misoprostol, 
83.8% (124 of 148 women; 95% confidence in-
terval [CI], 76.8-89.3) had complete expulsion 
within 1 to 3 days, compared to 67.1% (100 of 
149 women; 95% CI, 59-74.6) in the misoprostol 
alone group. The number needed to treat with 
mifepristone and misoprostol to achieve com-
plete expulsion at the first follow-up visit was 
6. The percentage of patients receiving uterine 
aspiration was lower in the mifepristone and 
misoprostol group (8.8%) than in the  misopro-
stol alone group (23.5%; relative risk =  0.37; 95% 
CI, 0.21-0.68). There were no significant differ-
ences in adverse events including bleeding in-
tensity, pelvic infection, or pain. 
WHAT’S NEW
A high-quality RCT  
demonstrates improved efficacy
Prior studies that have looked at combined 
mifepristone and misoprostol treatment for 
early pregnancy loss had heterogeneity in 
outcome definitions and study designs lead-
ing to variable reports of effectiveness.1,5 This 
is the first high-quality, randomized trial to 
demonstrate the safety and efficacy of oral 
mifepristone pretreatment prior to misopro-
stol vaginal administration in the medical 
management of early pregnancy loss.
CAVEATS
Would a placebo group—or other forms 
of misoprostol—change the results?
The study did not include a placebo group; 
however, an investigator who was blinded to 
the treatment group allocation determined 
the primary outcome, and the lack of placebo 
did not introduce bias related to the outcomes.
Intravaginal misoprostol was used in this 
study, rather than oral, rectal, buccal, or sub-
lingual misoprostol.7 It is not clear from this 
study if the results of pretreatment with mife-
pristone would be different if misoprostol was 
administered via one of these other routes. 
CHALLENGES TO IMPLEMENTATION
FDA restrictions limit  
availability of mifepristone
The main challenge to implementation is the 
availability of mifepristone. Mifepristone was 
approved by the US Food and Drug Admin-
istration in 2000. The approval included Risk 
Evaluation and Mitigation Strategy (REMS) 
 restrictions, stipulating that a health provider 
be specially certified for prescribing;  dispensing 
must occur in clinics, medical offices, or hos-
pitals; and patients must sign a patient agree-
ment form prior to obtaining the agent.8        JFP
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breast cancer findings, many clinicians look 
to alternative, nonoral dosage forms to im-
prove the safety profile. 
z Safety of nonoral estrogen therapy. 
Administration of nonoral estrogen is asso-
ciated with avoidance of hepatic first-pass 
metabolism and a resulting lower impact on 
hepatic proteins. Thus, data indicate a poten-
tially lower risk for venous thromboembolic 
events with transdermal estrogen compared to 
oral estrogen.1 Since the publication of the re-
sults of the WHI trials, prescribing patterns in 
the United States indicate a general decline in 
the proportion of oral hormones, while trans-
dermal prescription volume has remained 
steady, and the use of vaginal formulations has 
increased.2
z Topical estrogen formulations. Trans-
dermal or topical delivery of estrogen can 
be achieved through various formulations, 
including patches, gels, and a spray. While 
patches are simple to use, some women dis-
play hypersensitivity to the adhesive. Use of 
gel and spray formulations avoids exposure to 
adhesives, but these pose a risk of transfer of 
hormonal ingredients that are not covered by 
a patch. This risk is amplified by the relative 
accessibility of the product-specific applica-
tion sites, which include the arms or thighs. 
Each manufacturer recommends careful 
handwashing after handling the product, a 
specific drying time before the user covers 
the site with clothing, and avoidance of con-
tact with the application site for a prescribed 
period of time, usually at least 1 to 2 hours.3-6
z Our patient. This case illustrates the 
importance of discussing the risk of medi-
cation transfer to both humans and animals 
when prescribing individualized hormone 
therapy. While the Evamist prescribing in-
formation specifically addresses the risk of 
unintentional medication transfer to children, 
it does not discuss other contact risks.6  In the 
literature, there have been a limited number of 
reports on the adverse effects from transder-
mal or topical human medication transfer to 
pets. Notably, the American Pet Products As-
sociation estimates that in the United States, 
approximately 90 million dogs and 94 million 
cats are owned as a pet in 67% of households.7 
THE TAKEAWAY 
Use of HRT, including transdermal or topical 
estrogen formulations, is common. Given the 
large number of companion animals in the 
United States, physicians should consider 
that all members of a patient’s household—
including pets—may be subject to uninten-
tional secondary exposure to topical estrogen 
formulations and that they may experience 
adverse effects. This presents an opportunity 
for patient education, which can have a larger 
impact on all occupants of the home.          JFP
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